Department of Justice Seeks Public Comment on Tennessee Death Penalty Lawyers Request Estimated reading time: 3–5 minutes On August 7, 2025, the Department of Justice published a notice about Tennessee’s request for federal certification of its capital counsel mechanism. The State of Tennessee has asked the U.S. Attorney General for certification of its system to provide lawyers for people sentenced to death. The state wants approval that it meets federal rules for appointing, paying, and supporting lawyers for those who cannot afford legal help in death penalty cases. The rules for this come from Chapter 154 of Title 28 in the United States Code. These rules give states special procedures for federal court review of death penalty cases, but only if the state has set up a fair way for poor prisoners to get qualified lawyers and pay their legal costs. Now, the public can send comments about Tennessee’s request. People can write or make electronic comments until October 6, 2025. Mailed comments must be postmarked by that date. Online comments are open until Midnight Eastern Time on October 6, 2025. Comments must say “Docket No. OLP180” to help the Department handle them correctly. Electronic comments should be sent via www.regulations.gov. Paper comments should not copy the electronic version. For questions, contact Levi Lall, Counsel at the Office of Legal Policy, U.S. Department of Justice, 950 Pennsylvania Avenue NW, Washington, DC 20530. Phone: 202-598-0771. The public can read Tennessee’s request and the facts supporting it at https://www.justice.gov/olp/pending-requests-final-decisions. This notice was signed by Nicholas J. Schilling Jr., Supervisory Official in the Office of Legal Policy, on August 4, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Proposes Permanent Schedule I Placement for Five Designer Benzodiazepines Estimated reading time: 4–5 minutes The Drug Enforcement Administration (DEA) has announced a proposed rule to place five substances—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—in Schedule I of the Controlled Substances Act (CSA). The proposal includes each substance and its salts, isomers, and salts of isomers. These substances were temporarily placed in Schedule I on July 26, 2023, due to concerns about an imminent hazard to public safety. The temporary order was later extended to July 26, 2026. If this proposed rule is finalized, it will make these controls permanent. Why Are These Substances Being Scheduled? According to the DEA, these five substances have a high potential for abuse. They are chemically and pharmacologically similar to classical benzodiazepines, like diazepam and alprazolam. These classical drugs are widely abused and can cause dependence. The DEA and the Department of Health and Human Services (HHS) reviewed scientific and medical evidence about these substances. The review found that: They are not approved for any medical use in the United States. There are no accepted safety standards for their use under medical supervision. They have been linked to abuse, dependence, and serious health risks. Evidence and Data No legitimate sources, such as approved medicines, exist for these five substances in the United States. They are not used or manufactured legally and are mostly obtained from illegal sources or foreign countries. The DEA and HHS collected the following data: Over 50,000 encounters of these substances by law enforcement, from every state and Washington, DC. Evidence from U.S. poison centers and toxicology programs showing hundreds of cases involving these drugs, including deadly overdoses. Studies and user reports showing these drugs can cause strong sedative effects, impaired driving, and physical dependence. Some are more potent than known prescription benzodiazepines. Risks to Public Health The five substances act as strong depressants on the central nervous system. They can cause drowsiness, confusion, poor coordination, and breathing trouble. People have died from overdoses involving these drugs, especially when mixed with other substances like opioids. Reports show that people of all adult ages, and both sexes, have been harmed. Often, these drugs are used alone or with other dangerous drugs like fentanyl or stimulants. Legal and International Obligations The United States is required by the United Nations Convention on Psychotropic Substances (1971) to control these substances because other countries voted to add them to international lists. What Will Happen Under Permanent Scheduling? If permanently placed in Schedule I: It will be illegal to manufacture, distribute, import, export, or possess these substances except for DEA-approved research. They will be subject to strict storage and recordkeeping rules. Only DEA-registered persons will be allowed to handle these substances. Penalties for unauthorized activity would include criminal, civil, and administrative actions. Public Input and Comments The public can comment on this proposed rule until August 25, 2025. Comments can be made electronically at regulations.gov or mailed to the DEA office. People who want a hearing must ask before the same deadline. Small Business Impact DEA states that very few suppliers or researchers use these substances for legal research. The rule is not expected to impact a significant number of small businesses. How the Rule Changes Regulations If the rule becomes final, it will remove the substances from the temporary list and add them to the permanent list of Schedule I controlled substances under 21 CFR 1308.11(e). Contact Information For more information, contact Dr. Terrence L. Boos at the DEA, phone: (571) 362-3249. Conclusion The DEA’s proposal aims to keep U.S. laws in line with international treaties and protect public health. Clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam will remain closely controlled due to the dangers they pose. The public is invited to review and comment before the rule is finalized. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Extends Temporary Ban on Five Designer Benzodiazepines Until 2026 Estimated reading time: 3–5 minutes What Are the Banned Substances? The substances included in this order are: Clonazolam Diclazepam Etizolam Flualprazolam Flubromazolam These include their salts, isomers, and salts of isomers. Background On July 26, 2023, the DEA first placed these five substances under Schedule I due to an “imminent hazard to the public safety.” That two-year ban was set to end on July 26, 2025. The DEA says it needs more time to finish permanent scheduling rules. Legal Process The Controlled Substances Act allows the DEA to make temporary bans for up to two years. The ban can be extended for one more year if work to make the ban permanent is not finished. The Acting Administrator of the DEA started the process for a permanent ban. The DEA is publishing a notice of proposed rulemaking about this in the Federal Register. Regulatory Details The extension of the ban is not a regular rule but an order. This order is not subject to notice-and-comment rulemaking. The extension uses authority under 21 U.S.C. 811(h), which allows an expedited action to avoid risks to public safety. The DEA says that more delays would be against the public interest. Not extending the ban now could create risks if the substances became legal again before permanent rules are ready. Impacts on the Public Under Schedule I, these drugs are illegal to make, distribute, import, export, research, or possess unless specially permitted. Anyone handling these substances is subject to the same controls and penalties as with other Schedule I drugs. Why the Ban? The DEA explains that these five designer benzodiazepines pose a risk to public health. They used their emergency powers to make and extend this temporary ban. Administrative Information The order was signed on July 22, 2025, by Acting Administrator Robert J. Murphy. The official document was filed for publication and sent to both Houses of Congress and to the Comptroller General, although this is not legally required since it is an order, not a rule. Effective Date The order is effective July 26, 2025, and will stay in effect until July 26, 2026, unless permanent rules are made before then. Contact Questions can be directed to Terrence L. Boos, Drug and Chemical Evaluation Section, Diversion Control Division, DEA, at 8701 Morrissette Drive, Springfield, VA 22152, phone (571) 362-3249. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Requests Comments on New User Access Form for EPIC System Portal Estimated reading time: 3–5 minutes The Drug Enforcement Administration (DEA), part of the Department of Justice (DOJ), has announced a new information collection request. The form is called the User Access Request Form for the EPIC System Portal (ESP). This form will be used by law enforcement personnel at the federal, state, local, and tribal levels. They need this form to request access to the El Paso Intelligence Center (EPIC) System Portal. The portal lets approved users see information about drug and human trafficking, firearms smuggling, money laundering, and other crimes. The DEA is submitting this request to the Office of Management and Budget (OMB) for review, following the Paperwork Reduction Act of 1995. Public comments about the request are open for 60 days, ending September 23, 2025. The Department asks the public and other agencies to give feedback. They want comments on: Whether this information collection is needed. If the estimates about the burden on the public are correct. How the information collected can be improved for quality and usefulness. How to reduce the effort required to fill out the form, including by using better technology or allowing electronic submissions. The main purpose of the form is to collect enough information to approve new users for the EPIC System Portal. It is important for security and to meet federal law enforcement rules. Key Details of the Information Collection: Type: New collection. Title: User Access Request Form for the EPIC System Portal. Form Number: To be assigned after OMB approval. The Drug Enforcement Administration is responsible for this form. Who is Affected: Federal, state, local, and tribal law enforcement personnel wanting to access the portal. Filling out the form is required to get access. Estimated Respondents: 1,000 people per year. Time Per Response: About 7 minutes per form. Total Burden: 1,000 responses are expected each year, leading to a total estimated burden of 116.67 hours per year. Annual Cost Burden: The estimated yearly cost of this information collection is $4,666.80. The Department noted that the total burden hours and cost are based on the number of people expected to fill out the form and the time needed. Those seeking more information or a copy of the form may contact Benjamin Inks at the Office of Compliance, Policy Administration Section, Arlington, VA (telephone: 571-672-4524). For general questions, Darwin Arceo is listed as the Department Clearance Officer at the Justice Management Division, Washington, DC. Notice issued: July 23, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Bytecode Alliance Foundation Updates Membership in Official Notice Estimated reading time: 2–3 minutes On May 29, 2025, the Bytecode Alliance Foundation filed an official notification under section 6(a) of the National Cooperative Research and Production Act of 1993. This law is found at 15 U.S.C. 4301 et seq. The notification was sent to both the Attorney General and the Federal Trade Commission. It shared changes in the group’s membership. Renderlet, Inc., located in Brooklyn, New York, has joined the Bytecode Alliance Foundation as a party to this venture. SingleStore, based in San Francisco, California, has withdrawn as a party from this venture. No other changes have been made in the membership or the planned activity of the group research project. Membership in this group research project is still open. The Bytecode Alliance Foundation plans to send more written notifications for all membership changes in the future. The Bytecode Alliance Foundation first filed its original notification on April 20, 2022, under section 6(a) of the Act. The Department of Justice published a notice in the Federal Register under section 6(b) of the Act on May 13, 2022. The citation is 87 FR 29379. The last notification before this was filed on March 19, 2025. A notice was published in the Federal Register on April 21, 2025. The citation is 90 FR 16704. Suzanne Morris, Deputy Director of Civil Enforcement Operations in the Antitrust Division, signed the notice. The official Federal Register document number is 2025-14051. This notice was filed on July 24, 2025, and appeared in Volume 90, Number 141 on page 35313. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

New Members and Withdrawals in 1EdTech Consortium Announced Estimated reading time: 3–5 minutes The Department of Justice Antitrust Division released a notice about the 1EdTech Consortium, Inc. This notice was published in the Federal Register, Volume 90, Number 141, on Friday, July 25, 2025. The notice states that 1EdTech Consortium, Inc. filed a report on May 29, 2025. This report was sent to both the Attorney General and the Federal Trade Commission. The report was made according to the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. The report says that new members have joined the 1EdTech Consortium. The new members are: Aurora Public Schools (CO), Aurora, CO University of North Carolina Greensboro, Greensboro, NC Tuscaloosa City Schools, Tuscaloosa, AL Terrace Metrics, Inc., Cincinnati, OH Texas Education Agency, Austin, TX ViewSonic Education Agency, Brea, CA Morgan State University, Baltimore, MD The University of Texas Medical Branch, Galveston, TX International Baccalaureate Organization, Cardiff, UNITED KINGDOM Navigatr, Leeds, UNITED KINGDOM Alexander Becker (individual member), Berlin, FEDERAL REPUBLIC OF GERMANY The following groups or companies have withdrawn from 1EdTech Consortium: KERIS, Dong-gu, REPUBLIC OF KOREA Udemy, San Francisco, CA Cisco, San Jose, CA Swedish National Agency for Education (Statens skolverk), Solna, KINGDOM OF SWEDEN Partners4Results, Waukesha, WI Switch Energy Alliance, Austin, TX Siemens, Munich, FEDERAL REPUBLIC OF GERMANY There are no further changes in membership or planned activities. The membership for this group remains open. 1EdTech Consortium plans to file more updates about membership changes. The 1EdTech Consortium first reported its activities under the law on April 7, 2000. The Department of Justice first published a related notice on September 13, 2000 (65 FR 55283). The most recent earlier notification was made on March 17, 2025. That notice was published in the Federal Register on April 21, 2025 (90 FR 16702). Suzanne Morris, Deputy Director for Civil Enforcement Operations in the Antitrust Division, signed the notice. The official Federal Register document identifier is FR Doc. 2025-14054. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Notice of Membership Change in Decentralized Storage Alliance Association Estimated reading time: 2–4 minutes On July 25, 2025, the Department of Justice Antitrust Division published a notice in the Federal Register about changes in the Decentralized Storage Alliance Association (DSAA). The notice states that on May 27, 2025, DSAA filed written notifications with both the Attorney General and the Federal Trade Commission. This action was done under the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. The filing’s purpose is to extend legal protections. It limits the damages that antitrust plaintiffs can recover to actual damages under specific conditions. MetaProof Inc., based in New York, NY, has been added as a party to the DSAA venture. No other changes have been made to the membership or the group’s planned activities. Membership in the research project is still open. DSAA plans to keep the Department updated about future changes in membership. DSAA originally filed notification under the Act on August 1, 2023. The Department published information about this in the Federal Register on October 6, 2023 (88 FR 69670). The previous update was filed on December 9, 2024. That notice was published on February 3, 2025 (90 FR 8816). This notice was issued by Suzanne Morris, Deputy Director, Civil Enforcement Operations, Antitrust Division. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

America’s DataHub Consortium Updates Membership Estimated reading time: 3 minutes On June 16, 2025, America’s DataHub Consortium (ADC) sent official notifications about changes in its membership. These notifications were given to the Attorney General and the Federal Trade Commission. This action follows the National Cooperative Research and Production Act of 1993. The new members joining ADC are: 22nd Century Technologies, Inc., McLean, VA Daniel H. Wagner Associates, Inc., Hampton, VA Discovery Machine, Inc., Williamsport, PA Industry Defense Systems LLC, Lansdale, PA ISSAC LLC, Colorado Springs, CO JLGOV LLC, Virginia Beach, VA L3Harris Technologies, Inc., Clifton, NJ Magnum Multimedia, Inc., Herndon, VA Turnkey Federal LLC, Tampa, FL Two members have left the consortium: JIL NZ LLC, Chevy Chase, MD ZCTS LLC, Arlington, VA No other changes were made to the group’s membership or its planned activities. Membership in this group remains open. ADC will continue to provide notifications about future changes in its membership. ADC first filed notification under the Act on November 11, 2021. The Department of Justice published a notice about that filing on December 22, 2021 (86 FR 72628). The most recent notification before this one was filed with the Department on March 6, 2025. A notice for the March 2025 filing was published in the Federal Register on April 21, 2025 (90 FR 16702). Suzanne Morris, Deputy Director of Civil Enforcement Operations for the Antitrust Division, reported this information in the Federal Register on July 25, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Registration of Dr. Taha Dias, M.D. in Florida Estimated reading time: 3–5 minutes Background and Order Issued On November 4, 2024, the DEA sent an Order to Show Cause (OSC) to Dr. Taha Dias. The DEA warned that he might lose his DEA registration. The DEA said Dr. Dias gave out prescriptions for controlled substances in ways that were not allowed by law. These actions were seen as inconsistent with public interest. The DEA cited violations of both federal and Florida state law. Service of Order A DEA Diversion Investigator (DI) served the OSC to Dr. Dias. The DI sent it by email and by mail to his registered addresses. On November 22, 2024, Dr. Dias spoke with the DI. He was told about the OSC and what it meant. Details of Violations Between July 2022 and December 2023, Dr. Dias gave prescriptions for controlled substances that were outside the usual course of professional practice. He did not follow federal law 21 CFR 1306.04(a) or Florida Statutes Sec. 456.44(3). Dr. Dias did not reply to the DEA’s charges. The DEA says this means Dr. Dias admits to the facts described in the OSC. Dr. Dias admitted he wrote nine prescriptions for promethazine with codeine to nine different people, knowing the drugs would be obtained by someone else and not those named. On July 5, 2022, he texted a local pharmacist about sending these prescriptions, which were not for a real medical reason. Dr. Dias also admitted he wrote nine prescriptions for controlled substances to a person named M.S. between December 9, 2022, and December 4, 2023. M.S. was in a correctional facility when these prescriptions were written. Dr. Dias did not do a medical exam or create a real doctor-patient relationship for these prescriptions either. In total, Dr. Dias gave out at least 18 prescriptions that had no real medical purpose and were not allowed by his profession’s rules. Legal Findings and Process The DEA stated that under federal and Florida law, doctors must only prescribe controlled substances for real medical reasons and after proper exams. They must keep detailed patient records. The DEA found Dr. Dias did not follow these rules. In cases like this, the DEA checks five factors to decide if someone should keep their registration. The DEA mainly considered Dr. Dias’s compliance with laws and his experience with controlled substances. No evidence was found of state medical license problems or crime convictions for Dr. Dias. But the DEA said the main problem was how Dr. Dias prescribed the drugs. Sanction and Final Decision The DEA said Dr. Dias did not reply to the charges or try to explain his actions. He did not show he accepted responsibility or would follow the law in the future. Because of these reasons, the DEA revoked Dr. Dias’s DEA Certificate of Registration No. BD9971208. The DEA also denied any of his pending applications to renew or change his registration or to apply for a new registration in Florida. This order takes effect on August 25, 2025. Signed Order The order was signed on July 21, 2025, by Acting Administrator Robert J. Murphy. Reference: Federal Register, Volume 90, Number 141, Friday, July 25, 2025, Pages 35313-35315. [FR Doc No: 2025-14077] Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Seeks Public Comment on Movie Theater Accessibility Notice Requirements Estimated reading time: 4–9 minutes The Department of Justice (DOJ), Civil Rights Division, is asking for public comments on the rules that require movie theaters to tell people if closed movie captioning and audio description are available for digital movies. This request is part of a review by the Office of Management and Budget (OMB). Why This is Happening Under Title III of the Americans with Disabilities Act (ADA), movie theaters must not discriminate against people with disabilities. Federal law at 42 U.S.C. 12182 says that public places like movie theaters must provide aids and services for people with disabilities. Movie theaters that show digital movies and offer captioning or audio description must make sure all their notices—including signs at the box office, on websites, mobile apps, in newspapers, or over the phone—tell people which movies have these services. This is required by the rule at 28 CFR 36.303(g)(8). Who Must Follow These Rules These rules apply to any business or not-for-profit group that owns, operates, or leases a movie theater (but not drive-in theaters) that shows digital movies to the public for a fee. All theater firms that show digital movies with these features must let the public know in their movie listings if closed captioning or audio description is available. It is mandatory for these firms to follow this rule. Details About the Requirement The DOJ says that almost all U.S. movie theaters now show digital movies that can have closed captions and audio descriptions. Whenever these theaters tell the public about movie showings—such as by updating weekly movie listings—they must include information about the availability of these accessibility features. Estimated Effort to Meet the Requirement There are about 1,813 firms in the U.S. owning one or more movie theaters, according to 2022 U.S. Census Bureau data. Each firm is expected to spend about 10 minutes per week updating movie listings for closed captions and audio description information. Over a year, this is about 8.7 hours per firm for complying with the requirement. Summary Table of Burden Activity Number of Respondents Times per Year Total Responses Time per Response (minutes) Total Annual Hours Weekly update of movie listings 1,813 52 94,276 10 15,713 Total Annual Estimated Hours All firms together are expected to spend about 15,713 hours yearly to meet this requirement. Estimated Cost There is no new cost for theaters to meet this rule. Updating movie listings is already a normal part of movie theater business. The extra work to add symbols or notes about accessibility features is considered small. How to Give Comments Anyone can send comments until September 23, 2025. Comments should focus on: If the information is needed, If the burden estimates are correct, Ways to improve the quality and clarity, Ideas to make responding easier. Comments can be sent by mail to the Department of Justice in Washington, DC, by email, or to the Office of Management and Budget. Make sure to include the title: “Requirement that Movie Theaters Provide Notice as to the Availability of Closed Movie Captioning and Audio Description for Digital Movies.” Who to Contact for More Information For more information about this plan or to get materials in another format, contact Roberta Kirkendall, Special Litigation Counsel, Disability Rights Section, Civil Rights Division, U.S. Department of Justice, by mail or call the ADA Information Line at (800) 514-0301 (voice) or (800) 514-0383 (TTY). Conclusion This required information helps people with hearing or vision disabilities learn which digital movies have closed captions or audio description. The DOJ is seeking public comments before the rules become final. Published: July 25, 2025 Federal Register, Volume 90, Issue 141 Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Seeks Public Comments on National Crime Victimization Survey Changes Estimated reading time: 4–6 minutes On July 24, 2025, the Department of Justice (DOJ), Bureau of Justice Statistics (BJS), published a notice in the Federal Register about the National Crime Victimization Survey (NCVS). The BJS is asking the public for comments on a planned update for the NCVS. The updates must be approved by the Office of Management and Budget (OMB). The public can send comments for 60 days, ending on September 22, 2025. The NCVS collects national information about how often people in the United States experience crime. The survey counts crimes both reported and not reported to the police. The NCVS also collects data on how police handle reports and how safe people feel in their communities. Every so often, the survey process is updated. The 2026 update uses new methods to better represent the U.S. population using 2020 census data. Details of the Collection: Type: This is a revision of a currently approved collection. Title: National Crime Victimization Survey. Form Numbers: NCVS-1 and NCVS-2. Agency: Bureau of Justice Statistics, Office of Justice Programs. Who Responds: U.S. residents age 12 or older living in selected households. Responding is voluntary. Estimates for the Survey: Total Respondents per Year: 157,439 people. Time to Complete Survey (Average Interview): 34.4 minutes. Time for Non-Interviewed Respondents: 9.3 minutes. Follow-up Interview Time: 7 minutes. Follow-up for Non-interview: 1 minute. Annual Burden (Total Hours): 123,202 hours. Annual Cost Burden: $0. Burden Hours by Activity: Activity Respondents Frequency Annual Responses Time per Response (minutes) Annual Burden (hours) Interviewed 91,312 2 182,624 34.4 104,698 Non-interviewed 56,772 2 113,544 9.3 17,599 Re-interview (Interviews) 7,484 1 7,484 7.0 873 Re-interview (Non-interviews) 1,871 1 1,871 1.0 31 Unduplicated Totals 157,439 — 305,523 — 123,202 How to Comment or Get More Information: Those with suggestions or questions can contact Rachel Morgan, Chief of the Victimization Statistics Unit at the BJS. Her office is located at 999 N Capitol Street NE, Washington, DC 20531. Email and phone contacts are also provided: [email protected], 202-307-0765. For further information, Darwin Arceo, Department Clearance Officer at the DOJ, is also listed as a contact. Key Points for Comments: The DOJ asks the public to focus on these points in their comments: Is the survey needed for the BJS to do its job well? Are the time estimates and methods correct? Can the collected information be improved? Can the burden on respondents be reduced by using technology? The deadline for public comments is September 22, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Proposes New Data Collection for Violence Against Women Act Grants Estimated reading time: 4–6 minutes The Office on Violence Against Women (OVW), part of the Department of Justice, has announced a new proposal for collecting information from grantees of programs under the Violence Against Women Act (VAWA). These changes are explained in a notice published in the Federal Register on July 24, 2025. What is the New Plan? The OVW wants to combine 19 current performance reporting forms into one new, streamlined system. This system will collect data from groups that receive money under VAWA. It will cover both “formula” programs, such as STOP and SASP, and “discretionary” programs. This means all grantees and subgrantees will use the same online reporting platform. Who Will Use This System? The new system will be used by: Formula grant program administrators Formula grant subgrantees Discretionary grant program grantees These groups include local, state, and tribal governments, courts, non-profits, schools, colleges, coalitions, and other groups. How Does It Work? The new system uses a web-based form. The form is tailored for each grant program. Grantees will only complete sections about activities funded by their grant. Why Change the Old System? Currently, 19 different forms are in use, collecting similar or repetitive data in different ways. The new plan will: Make reporting easier and faster Use clearer questions Cut out repeated questions Allow electronic submission This is expected to improve the quality, usability, and consistency of the data. It will also make future updates easier if VAWA or government needs change. How Much Work Will This Involve? The estimate for reporting is: About 6,112 groups will need to report Each form takes about 60 minutes to complete The workload for each group is: Formula administrators: 112 responses per year (once a year per respondent) Formula subgrantees: 3,000 responses per year (once per respondent) Discretionary grantees: 6,000 responses per year (twice per respondent) The total amount of reporting time is estimated at 9,112 hours per year. How Much Does It Cost? The OVW estimates the total annual cost to review the reports and keep the system running is $800,000. What Happens Next? This is a proposed plan. The OVW wants public feedback. Comments will be accepted until September 22, 2025. If you have questions or want to comment, contact Tiffany Watson at the Office on Violence Against Women at 202-307-6026, or email OVW for a copy of the collection instrument or more information. Conclusion The Department of Justice is working to make it easier and faster for groups to report on activities funded by Violence Against Women Act grants. The new system is designed to cut paperwork and improve the way data is collected and used. Groups affected by these changes can learn more and share their feedback before September 22. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Proposes Changes to National Prisoner Statistics Program Estimated reading time: 4–6 minutes The Bureau of Justice Statistics (BJS), a part of the U.S. Department of Justice, is planning to update the National Prisoner Statistics program (NPS). The BJS has asked the public for comments on this plan. Comments will be accepted for 60 days, ending on September 22, 2025. Information Collected The NPS program collects yearly numbers about prisoners held by state and federal prisons. It tracks the number of people admitted and released. The information is used to report on how people move through the prison system each year. This helps the BJS show changes in the prison population and supports the work of many people. Key Changes One change is that questions about HIV/AIDS will be removed. These may come back in special health supplements in the future. The BJS also plans to test a new way to collect race and ethnicity data. This matches the rules in the 2024 OMB Statistical Policy Directive No. 15. The BJS will also check if more race and ethnicity data can be collected from the current data systems. Who Must Report NPS-1B: Used by 51 reporters (one from each state and the Federal Bureau of Prisons). NPS-1B(T): Used by five reporters from U.S. Territories or Commonwealths (Guam, Puerto Rico, Northern Mariana Islands, Virgin Islands, American Samoa). Information Required from States and Federal Prisons Each year, the 51 reporters must give details including: The number of men and women in prison as of December 31, sorted by sentence length and if they are unsentenced. How many people are housed in private, county, or other facilities. Admission types: new court commitments, parole violators, other transfers, and returns. Release types: finished sentences, commutations, probation, parole, deaths by cause, transfers, and other categories. Prisoners by race and Hispanic origin. U.S. citizenship status of prisoners. The source used for citizenship data. The capacities of prisons, broken down by sex. Information Required from Territories and Commonwealths Each year, the five reporters from the territories must provide: Number of men and women in prison as of December 31 by sentence length, and how complete those numbers are. People sent to other places to reduce overcrowding. Prisoners by race and Hispanic origin. The end-of-year capacities of correctional facilities by sex. Why This Matters The Bureau of Justice Statistics uses the collected information for government reports. These reports are used by Congress, the President, researchers, students, media, and others interested in crime and justice data. Response Details Responding to the survey is voluntary. Each of the 51 main respondents will spend about 4.5 hours each year on the NPS-1B form. The five territory respondents will each spend about 2 hours on the NPS-1B(T) form. The total estimated burden is 795 hours over three years, or about 265 hours per year. The overall cost for all respondents is estimated at $577,000 per year. Contact Information For questions or copies of the data collection forms, contact Derek Mueller, Bureau of Justice Statistics, at 999 N Capitol St. NE, Washington, DC 20531, or call 202-307-0765. If you need more information, you can also contact Darwin Arceo at the Department of Justice, 145 N Street NE, Washington, DC 20530. Publication Information This notice was published in the Federal Register, Volume 90, Number 140, on July 24, 2025. The notice number is 2025-13933. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DOJ Announces Proposed Changes to Federal Firearms Licensee NICS Forms Estimated reading time: 2-3 minutes The Department of Justice (DOJ), through the Federal Bureau of Investigation (FBI), has announced a proposed revision to the information collection for Federal Firearms Licensees (FFLs). This proposal was published in the Federal Register on July 24, 2025. The revision concerns important forms related to the National Instant Criminal Background Check System (NICS). These forms include the FFL Enrollment/NICS E-Check Enrollment Form, the FFL Officer/Employee Acknowledgment of Responsibilities under the NICS Form, and the Responsibilities of an FFL under the NICS Form. The FBI is inviting public comments on the proposed changes. The comment period is open for 60 days, ending September 22, 2025. The changes include adding four new fields to the form. The new questions ask for the FFL’s date of birth and the mother’s maiden name for security reasons. There is also a new question for FFLs in Point of Contact (POC) states. If the FFL operates in a POC state, they must confirm they will use the FBI NICS system for authorized purposes only. The main purpose of collecting this information is to control access to the NICS and NICS Electronic (E-Check) systems. The forms help protect the privacy and security of background check information. They ensure only authorized users, like FFLs and employees in POC states, can use the NICS system. The DOJ estimates that 6,160 respondents will complete these forms each year. Completing and reading the forms takes about 15 minutes per person. This results in a total estimated burden of 1,540 hours yearly. The cost for respondents is $0, as the forms are available online and can be signed digitally. No mailing or copying costs are required. The responses are required for FFLs or POC states to obtain access to the NICS system to perform background checks for firearm sales. Anyone needing more information or wishing to review the proposed information collection can contact Jill Montgomery at the FBI NICS Section in Clarksburg, West Virginia. For official details or to send in comments, the announcement provides contact information for Darwin Arceo, the Department Clearance Officer at the Department of Justice. More information on the NICS is available at https://www.fbi.gov/services/cjis/nics. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

U.S. Marshals Service Requests Comments on Special Deputation Forms Estimated reading time: 3–5 minutes The U.S. Marshals Service (USMS) is seeking public comments on its Special Deputation Forms. This request was announced by the Department of Justice in the Federal Register, Volume 90, Number 140, on July 24, 2025. The USMS wants to collect feedback as part of a review required by the Paperwork Reduction Act of 1995. Comments are being accepted for 60 days, ending on September 22, 2025. Collection Details The USMS is revising its current approval for forms used in the Special Deputation Program. These forms help record and track people deputized to act as Special Deputy U.S. Marshals. Special Deputation is permitted when law enforcement needs arise, as decided by the Associate Attorney General under 28 CFR 0.19(a)(3). There are two main forms: USM-3A: Application for Special Deputation/Sponsoring Federal Agency Information. USM-3C: Group Special Deputation Request. These forms are completed by State, Local, and Tribal Governments. Estimated Usage and Burden USM-3A: It is estimated that 8,000 respondents will use this form every year. Each form will take about 10 minutes to complete. This adds up to around 1,333 total annual burden hours. USM-3C: Around 300 respondents are expected to use this form annually, with each taking about 15 minutes. This totals 75 annual burden hours. The annual cost burden for both forms is estimated at $0.00. Table of Annual Burden Activity Number of Respondents Frequency (Annually) Total Annual Responses Time per Response (Mins) Total Annual Burden (Hours) USM-3A Application for Special Deputation 8,000 1 8,000 10 1,333 USM-3C Group Special Deputation Request 300 1 300 15 75 Total 8,300 1,408 Instructions for Comments The USMS is asking for comments about the following points: Is the information necessary for the agency’s work? Is the estimated burden and response time correct? Can the quality and clarity be improved? How can the burden on respondents be reduced, for example, by using electronic submissions? People needing more information or wishing to submit comments can contact Assistant Chief Karl Slazer, Management Support Division, US Marshals Service Headquarters, 1215 S Clark St., Ste. 10017, Arlington, VA 22202-4387. Phone: 703-740-2316, or email: [email protected]. If further information is needed, contact Darwin Arceo, Department Clearance Officer, Justice Management Division, U.S. Department of Justice. The notice is signed by Darwin Arceo, Department Clearance Officer for PRA, dated July 22, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Justice Department Corrects Notice on Immigration Appeal Form Fees After Recent Law Change Estimated reading time: 3–5 minutes The Department of Justice (DOJ) has released a correction regarding the collection of information for the Notice of Appeal From a Decision of an Immigration Judge, Form EOIR-26. The correction was published in the Federal Register on July 23, 2025, by the Executive Office for Immigration Review (EOIR). The update relates to an earlier notice that appeared in the Federal Register on July 1, 2025. This correction adds one more change to the information collection process. EOIR will submit the updated collection request to the Office of Management and Budget (OMB) for approval. This follows rules found in the Paperwork Reduction Act of 1995. The comment period for this proposed change is still open until September 2, 2025. Anyone needing more information or wishing to comment on the public burden, response time, or methods related to this collection, can contact Justine Fuga, Associate General Counsel, at the EOIR. Contact details are: Address: 5107 Leesburg Pike, Suite 2600, Falls Church, VA 22041 Telephone: (703) 305-0265 Email: [Contact information provided in the original source] The correction makes the instructions for how to file Form EOIR-26, both by mail and electronically, more clear. It also updates information about new filing fees. These fee changes are the result of the One Big Beautiful Bill Act (OBBBA), H.R. 1, which became law on July 4, 2025. The corrected estimated annual cost is $12,747,978 for the public. According to EOIR estimates: 12,487 responses each year come from applicants who have to pay a filing fee. 647 responses come from Department of Homeland Security Immigration and Customs Enforcement (DHS ICE) employees, who are not required to pay a filing fee. The cost per response is as follows: For regular applicants: $0.80 for printing, $10.10 for postage, and $1,010 for the filing fee. The total per response is $1,020.90. For DHS ICE: $0.80 for printing, $10.10 for postage, and no filing fee. The total per response is $10.90. Total annual costs are calculated as follows: $1,020.90 multiplied by 12,487 responses equals $12,747,978 for applicants required to pay. $10.90 multiplied by 647 responses equals $7,052 for DHS ICE. The correction is signed by Darwin Arceo, Department Clearance Officer for PRA, DOJ. This update ensures the information collection aligns with the new law and provides clarity on costs and filing instructions. The public and interested parties may continue to submit comments until September 2, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Proposes New Rules on Federal Firearm Rights Restoration Estimated reading time: 8–10 minutes On July 22, 2025, the Department of Justice published a proposed rule in the Federal Register. The rule sets out how people can apply for relief from federal laws that stop them from having guns. Why the Rule Is Needed The Gun Control Act makes it illegal for some people to have firearms. This includes people with certain criminal records, people with mental health commitments, and others considered dangerous. But the Act also gives people a way to ask for their rights back. This is called “relief from disabilities.” Before 2025, the Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF) handled these requests. Problems appeared. There were not enough rules for deciding who should get their rights back. Some dangerous people got their rights restored, and later, committed crimes. Because of this, Congress stopped ATF from using funds to process these applications in 1992. Recently, the Attorney General took authority away from ATF and announced a new rule would be made. About the Proposed Rule The new rule sets out clear criteria for granting relief. It tries to keep dangerous people from getting guns, while respecting the Second Amendment. Presumptive Disqualifications Convictions for violent or dangerous felonies like murder, sexual assault, kidnapping, domestic violence, burglary, robbery, arson, and more. Felony sex offenses. People required to register as sex offenders. Anyone convicted of a felony using guns or explosives. Anyone convicted in the past 10 years of drug distribution crimes. Anyone convicted in the past 10 years for a misdemeanor crime of domestic violence, or shown to still be violent. Anyone convicted in the past 5 years for other felony offenses. People currently in prison or on probation, parole, or supervision. People subject to certain other gun disqualifications (like being a fugitive, using illegal drugs, being under restraining orders, or being in the country illegally). Anyone denied under these rules in the past. Looking at the Whole Story The Attorney General can look at all the facts of a person’s case—not just the official name of the crime. This means the actual conduct, not just the law’s wording, is used to decide eligibility. The rule says applications will also require input from local law enforcement. What Applicants Must Do Applicants must give: Detailed records about past convictions. Proof that criminal sentences are completed. Reference letters from people not related to them. Personal affirmations about their behavior and character. Notification to the chief law enforcement officer in their area. Applicants must show they are not dangerous and that restoring their rights is in the public interest. Fees The Department estimates about 1 million people will apply in the first year. Applicants must pay a $20 fee (unless poor, then a waiver may be requested). This covers costs for handling the applications. Reviewing Applications The Attorney General will review each applicant’s full criminal record, behavior during supervision, time since release, current mental health, community reputation, drug or alcohol use, and more. Input from police chiefs or sheriffs will be considered. Any false information in the application can cause removal of granted rights. Other Points The relief applies only to federal gun laws. State gun bans are not changed by this rule. The rule applies to people and gun dealers. Changes are made to access federal gun background system records. If rights are restored but the person commits a new crime, the relief can be taken back. How to Comment Comments on the rule are due by October 20, 2025. People can use regulations.gov or mail a comment to the U.S. Department of Justice. Impact The Department says the rule will help protect public safety, make the process clearer, and allow fair restoration of rights. It says the new system will be fair and follow the law. For more details, see the Federal Register, Volume 90, Number 138, pages 34394–34405, dated July 22, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Requests Public Comments on EOIR-31 Form Renewal Estimated reading time: 6–10 minutes The Department of Justice (DOJ) has issued a notice about renewing the information collection for the EOIR-31 form. This form is used by non-profit religious, charitable, social service, or similar organizations to request recognition from the Executive Office for Immigration Review (EOIR). The EOIR wants public comments about this information collection. Comments will be accepted for 30 days, until August 18, 2025. The DOJ is asking for feedback on the form’s necessity, how much time it takes to fill out, how to make it better, and how to make it easier to complete, possibly with new technology. The notice says this review is required by the Paperwork Reduction Act of 1995. DOJ will submit the request to continue using this form to the Office of Management and Budget (OMB) for the next three years. The OMB cannot approve the form for more than three years without renewal. Form EOIR-31 is Used For: Requesting new recognition for an organization. Requesting renewal of recognition. Requesting to extend recognition from one office to another. The form lets organizations ask to be allowed to help people in immigration proceedings before EOIR and/or the Department of Homeland Security (DHS). This is only for non-profit organizations that want to provide legal services in immigration cases. The EOIR-31 form follows U.S. laws under 8 U.S.C. 1103, 1229a, 1362, and 8 CFR 1292.11-19. The form can be completed as a fillable PDF or through an electronic system. Recent changes to the form include updates to the Privacy Act notice, the expiration date for OMB approval, changes to the submission address, and another way to submit completed forms. Who Must Respond: Non-profit organizations who want to be recognized as legal service providers in immigration cases by the Assistant Director for Policy at EOIR. Obligation to Complete the Form: Filling out the form is voluntary. But, organizations that do not submit the required information may not have their recognition request considered. Estimated Number of Respondents Each Year: 210 organizations for new recognition. 90 organizations for renewal of recognition. 20 organizations for extension of recognition to another office. Estimated Time to Complete the Form: 2 hours for new recognition. 7 hours for renewal of recognition. 2 hours for extension to another office. Total Annual Time Burden: 1,090 hours for all respondents. Estimated Annual Other Costs: $0 (no cost except time for respondents). How to Submit Comments: Comments and recommendations should be submitted within 30 days of this notice. Go to www.reginfo.gov/public/do/PRAMain. Click on “Currently under 30-day Review—Open for Public Comments” or search for the title or OMB Control Number 1125-0012 to find this information collection. Need More Information? For details or a copy of the collection instrument, contact Justine Fuga, Associate General Counsel, Office of the General Counsel, Executive Office for Immigration Review, 5107 Leesburg Pike, Suite 2600, Falls Church, VA 22041. Telephone: (703) 305-0265. If you need further information, contact Darwin Arceo, Department Clearance Officer, Justice Management Division, U.S. Department of Justice, Two Constitution Square, 145 N Street NE, 4W-218 Washington, DC 20530. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Seeks Public Comments on Non-Attorney Representative Accreditation Form Estimated reading time: 4–6 minutes The Executive Office for Immigration Review (EOIR), part of the Department of Justice, is asking for public comments on a form used to request accreditation or renewal of accreditation for non-attorney representatives. This request is published in the Federal Register, Volume 90, Issue 136, on Friday, July 18, 2025. Background and Purpose The EOIR will send the information collection request for Form EOIR-31A to the Office of Management and Budget (OMB). This is for approval under the Paperwork Reduction Act of 1995. The collection is needed for non-profit organizations seeking accreditation for their representatives who are not attorneys. These representatives can help people in immigration cases before EOIR and the Department of Homeland Security (DHS). How to Comment Public comments are welcome for 30 days, until August 18, 2025. Comments can include: Whether the form is necessary for EOIR’s work and if it is useful. If the agency’s estimate of how much time the form takes is correct. Ways to make the form better or clearer. Suggestions to lessen the burden for people who fill out the form, including using electronic submissions. Written comments and recommendations should be submitted at www.reginfo.gov/public/do/PRAMain by searching for OMB Control Number 1125-0013 or the form’s title. Details of the Collection Type: Extension of a previously approved collection. Title: Request by Organization for Accreditation or Renewal Accreditation of Non-Attorney Representative. Form Number: EOIR-31A. Who Responds: Non-profit organizations that want their representatives accredited or reaccredited by the EOIR’s Assistant Director for Policy. Why the Form Is Important Organizations use this form to ask for accreditation for their representatives to appear in immigration court or before DHS. The form helps EOIR decide if representatives meet the legal requirements under 8 U.S.C. 1103, 1229a, 1362, and 8 CFR 1292.11-19. The latest changes to the form include an updated Privacy Act notice, expiration date, a new address for submissions, and a new electronic submission option. Is Responding Required? The form is voluntary. However, not providing the information may stop EOIR from considering an accreditation request. Estimated Numbers and Time Initial Accreditation: 747 respondents per year, each taking about 3 hours to complete. Renewal: 314 respondents per year, each taking about 7 hours to complete. Total Annual Respondents: 1,061. Total Annual Time Burden: 4,439 hours. Estimated Other Annual Costs: $0. Contact for More Information If you want more information about this collection, you can contact: Justine Fuga, Associate General Counsel, Office of the General Counsel Executive Office for Immigration Review 5107 Leesburg Pike, Suite 2600 Falls Church, VA 22041 Phone: (703) 305-0265 For further details, you may also contact Darwin Arceo, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, Department of Justice, 145 N Street NE, 4W-218, Washington, DC 20530. Document Details DARWIN ARCEO Department Clearance Officer for PRA U.S. Department of Justice Dated: July 16, 2025 Federal Register Document Number: 2025-13519 Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Webb’s Square Pharmacy Registration Over Illegal Drug Dispensing Estimated reading time: 4–8 minutes On July 14, 2025, the U.S. Drug Enforcement Administration (DEA) announced that it has revoked the DEA registration of JYA LLC, also known as Webb’s Square Pharmacy, located in Davenport, Florida. This decision comes after findings that the pharmacy dispensed controlled substances without valid prescriptions and against legal requirements. Background On November 18, 2024, Webb’s Square Pharmacy received an Order to Show Cause and Immediate Suspension of Registration. The DEA suspended the pharmacy’s Certificate of Registration (No. FJ2231570) because it believed that keeping the pharmacy registered was an imminent danger to the public. Hearing Process and Default The pharmacy’s contact person received the order in person on November 21, 2024. Under the law, the pharmacy had 30 days to ask for a hearing. The DEA states that the pharmacy did not request a hearing and did not respond to the charges. Because of this, the pharmacy is considered to have admitted all the facts in the order and is in default. Pharmacy Law and Responsibilities Pharmacies must follow the Controlled Substances Act (CSA). The law says controlled drugs can only be dispensed for a real medical reason and with a valid prescription from a doctor. Both doctors and pharmacists are responsible for following these rules. Florida law says a pharmacist must not fill a prescription if they believe it is not for a real medical purpose or if there is no true doctor-patient relationship. Pharmacists are supposed to check that any prescription for a controlled drug is valid and should refuse to fill it if they cannot resolve their concerns. Facts Admitted by Pharmacy According to the DEA, Webb’s Square Pharmacy: Dispensed about 312 prescriptions for controlled drugs between July 2022 and March 2024. Gave out controlled drugs after multiple text message conversations between the owner/pharmacist-in-charge and other parties, including a doctor and outside individuals. Knew or should have known that these were not legitimate prescriptions. Allowed third parties with no legitimate connection to patients to pick up drugs. Repeatedly did not attempt to check if prescriptions were real or for a valid medical purpose. Details of Unlawful Dispensing Some specific details include: In July 2022 and January 2023, the pharmacy filled multiple prescriptions for drugs like promethazine with codeine and oxycodone after arrangements between the pharmacist and a doctor, knowing the prescriptions were invalid. The pharmacy dispensed drugs like promethazine with codeine, alprazolam, and oxycodone for individuals who were not patients or who had no valid prescriptions. Prescriptions were often picked up by people with no medical relationship to the patients. Basis for Revocation The DEA concluded that the pharmacy violated both federal and Florida law many times by filling prescriptions it knew or should have known were not legitimate. The DEA also found that the pharmacy did not try to defend itself or explain its actions during the official process. There was no sign the pharmacy accepted responsibility or showed it could be trusted to follow the law in the future. Decision and Sanction Based on these facts, the DEA decided to revoke the pharmacy’s Certificate of Registration. The agency also denied any pending applications to renew or modify this registration and any new applications for registration in Florida. The order officially takes effect on August 13, 2025. Authority The order is issued under the authority of Acting DEA Administrator Robert J. Murphy and is filed by Heather Achbach, the DEA Federal Register Liaison Officer. Reference Federal Register, Volume 90, Number 132, Notice pages 31244-31247, Document No. 2025-13121, dated July 14, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Just Here II Pharmacy’s Registration in Philadelphia Estimated reading time: 4–6 minutes Reason for Revocation On October 24, 2024, the DEA sent Just Here II Pharmacy an Order to Show Cause and Immediate Suspension of Registrations. The order explained that the pharmacy’s actions posed an imminent danger to public health and safety. The DEA said the pharmacy’s recordkeeping and inventory practices for controlled substances were not accurate. This violated federal and Pennsylvania state laws. According to the DEA, the pharmacy was unable to account for thousands of doses of controlled substances during an audit. This included large discrepancies in the records of drugs like oxycodone, alprazolam, and promethazine with codeine. For example, the DEA found differences of up to 2,930 dosage units for some medications between the pharmacy’s dispensing reports and distributor order data. In some cases, the discrepancies were as high as 100 percent. Failure to Respond Just Here II Pharmacy did not respond to the OSC/ISO or request a hearing. The DEA considers this a “default,” meaning the pharmacy is treated as if it admitted to the DEA’s allegations. The OSC/ISO was properly served to the pharmacy’s Pharmacist in Charge. Controlled Substances Law The Controlled Substances Act (CSA) and its regulations require pharmacies to keep complete and accurate records of all controlled substances. Both federal and Pennsylvania state law require correct inventory and recordkeeping. Failing to record or maintain accurate data about controlled substances purchases, inventory, or sales breaks these laws. Investigation Findings The DEA determined that between September 27, 2023, and March 1, 2024, Just Here II Pharmacy did not keep accurate records. There were significant differences between the pharmacy’s dispensing data and what distributors recorded. This affected several types of controlled substances, such as: Approximately 200 dosage units of oxycodone HCL 5 mg Approximately 1,459 dosage units of oxycodone HCL 15 mg Approximately 2,930 dosage units of alprazolam 2 mg Approximately 2,839 dosage units of promethazine with codeine The DEA found that the pharmacy failed to maintain required initial and biennial inventories of its stock. Public Interest Decision The DEA considered its guidelines for public interest. Factors such as the pharmacy’s experience dispensing controlled substances and its compliance with laws were considered. The DEA found that Just Here II Pharmacy broke both state and federal laws. There was no evidence to show that the pharmacy could be trusted to follow the law in the future. Since the pharmacy did not participate in the process or accept responsibility, the DEA decided that revoking registration was necessary to protect public health and safety. Final Order The Acting Administrator of the DEA, Robert J. Murphy, signed the order on July 8, 2025. The DEA revoked the pharmacy’s registration and denied any pending applications for renewal or modification. The order takes effect on August 13, 2025. Summary Just Here II Pharmacy’s DEA registration is revoked. The decision is based on failures to keep correct records for controlled substances and not responding to the DEA’s actions. The DEA says this decision helps protect the public from the risks associated with improper recordkeeping of controlled drugs. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes John Hanley, P.A.’s Registration in New Mexico Estimated reading time: 1–7 minutes The Drug Enforcement Administration (DEA) has revoked the Certificate of Registration No. MH4317702 held by John Hanley, P.A. of Santa Fe, New Mexico. The order was published in the Federal Register on July 9, 2025. Reason for Revocation According to the DEA, John Hanley is not allowed to prescribe, dispense, or handle controlled substances in New Mexico. His registration was revoked because he does not have the required state license. The New Mexico Medical Board had revoked Hanley’s physician assistant license on or about February 27, 2024. Service of Notice The DEA attempted to contact Hanley at his last known home address. When they could not deliver the notice in person, the DEA emailed a copy of the Order to Show Cause to Hanley’s registered email address. The email was confirmed as delivered. Lack of Response and Default Hanley did not reply to the DEA’s Order to Show Cause. He did not request a hearing. Under DEA rules, if a registrant does not respond, it is considered a default. The person loses the right to a hearing. The allegations are then taken as true. Findings The DEA confirmed that Hanley is not licensed to practice as a physician assistant in New Mexico. This is based on the state’s online records. Legal Basis The Controlled Substances Act requires that anyone registered to handle controlled substances must be licensed in the state where they practice. If a state license is lost or revoked, the DEA must also revoke its registration. In New Mexico, a physician assistant must be licensed by the New Mexico Medical Board to prescribe or handle controlled substances. Without that state license, Hanley cannot legally work as a physician assistant or dispense controlled substances in New Mexico. Order Details The DEA has revoked John Hanley’s registration. The agency has also denied any ongoing or future applications to renew or modify his registration in New Mexico. This order becomes effective on August 8, 2025. Signing Authority The order was signed on July 2, 2025, by Acting Administrator Robert J. Murphy. Heather Achbach, Federal Register Liaison Officer, confirmed the document for publication. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Texas Doctor Andrew Jones, M.D.’s Controlled Substance Registrations Estimated reading time: 5–8 minutes On December 9, 2024, the Drug Enforcement Administration (DEA) sent an Order to Show Cause to Andrew Jones, M.D. of Houston, Texas. The DEA threatened to revoke his DEA Certificate of Registration numbers FJ3614826 and FJ9984154. The reason was that Dr. Jones no longer had the authority to prescribe, give out, or handle controlled substances in the state of Texas, where he was registered. Dr. Jones asked for a hearing and gave a Supplemental Answer. Later, the Government filed a Motion for Summary Disposition. Dr. Jones responded and supplied evidence. On February 11, 2025, Administrative Law Judge Teresa A. Wallbaum granted the Government’s Motion. She said Dr. Jones did not have Texas state authority to handle controlled substances. The judge said there was “no genuine issue of material fact in this case.” Dr. Jones did not file any exceptions to the judge’s recommended decision. The DEA reviewed the record and agreed with the judge’s findings. The DEA said it would take official notice that, on or about April 4, 2024, the Texas Medical Board temporarily restricted Dr. Jones’s medical license. Dr. Jones is not allowed to possess, give out, or prescribe controlled substances in Texas. State online records confirm that Dr. Jones’s license is active but remains restricted. The DEA explained that, by law, a practitioner must have state authority to handle controlled substances. If a doctor loses this authority, they cannot have a DEA registration. This rule is based on the Controlled Substances Act. The law says a practitioner must be licensed, registered, or allowed by the state to handle controlled substances. Without this, a doctor cannot prescribe or give out such drugs. According to the Texas law, “dispense” means delivering or prescribing a controlled substance as part of professional practice. Only practitioners licensed or otherwise allowed in Texas can do this. Since Dr. Jones lost his authority, he does not qualify for a DEA registration in Texas. As a result, the DEA has revoked Dr. Jones’s DEA Certificate of Registration numbers FJ3614826 and FJ9984154. The DEA also denied any pending applications from Dr. Jones to renew or change these registrations. Any other requests for registration by Dr. Jones in Texas are also denied. The order will be effective August 8, 2025. This order was signed by Acting Administrator Robert J. Murphy of the DEA on July 1, 2025. The document was submitted for publication by Heather Achbach, DEA Federal Register Liaison Officer. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Dr. Hayriye Gok’s Registration to Handle Controlled Substances in Pennsylvania Estimated reading time: 3–5 minutes On July 9, 2025, the Drug Enforcement Administration (DEA) announced it has revoked the Certificate of Registration for Hayriye Gok, M.D., of Philadelphia, Pennsylvania. This certificate allowed Dr. Gok to handle controlled substances in the state. The action came after the DEA issued an Order to Show Cause (OSC) against Dr. Gok on February 20, 2025. The DEA stated that Dr. Gok could not legally handle controlled substances in Pennsylvania because her state license to practice medicine had been suspended. Dr. Gok was notified about the OSC and was informed she had the right to ask for a hearing. She did not request a hearing. According to the DEA, when a person does not ask for a hearing, they are considered to have admitted the facts listed in the OSC. The DEA tried to reach Dr. Gok at her business address and by phone, but was not successful. The DEA then served the OSC to Dr. Gok by email. Dr. Gok replied and confirmed she received the notice, but she still did not ask for a hearing. The DEA checked Pennsylvania’s official online license records. As of the date of the order, Dr. Gok’s medical license showed a “Suspension” status. The Pennsylvania State Board of Medicine had temporarily suspended her license on November 21, 2024. The DEA orders are based on federal law. This law says that a physician must have a valid state license to get and keep a DEA registration to dispense controlled substances. Without a license, a doctor is not allowed to prescribe, administer, or handle these drugs. In Pennsylvania, a practitioner must be licensed or otherwise allowed to give out or prescribe a controlled substance. With Dr. Gok’s license suspended, she is not allowed to practice medicine or handle controlled substances in Pennsylvania. The DEA’s order also says that any pending applications by Dr. Gok to renew or change her registration, or to get a new registration in Pennsylvania, are denied. The DEA’s action is final and goes into effect on August 8, 2025. The order was signed by Acting Administrator Robert J. Murphy on July 1, 2025, and published in the Federal Register. Heather Achbach, the DEA Federal Register Liaison Officer, completed the filing for official publication. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Announces Proposed Consent Decree With Trialco Aluminum, LLC Estimated reading time: 3–5 minutes On July 2, 2025, the Department of Justice (DOJ) lodged a proposed Consent Decree with the United States District Court for the Northern District of Illinois. The case is called United States v. Trialco Aluminum, LLC, Civil Action No. 1:25-cv-07461. This Consent Decree tries to resolve claims against Trialco Aluminum, LLC. The claims are about the company’s emissions of hazardous air pollutants at its aluminum production facility. This facility is located in Chicago Heights, Illinois. The complaint in this case asks for both injunctive relief and civil penalties. It is brought under Section 113(b) of the Clean Air Act (CAA), which is 42 U.S.C. 7413(b). It claims that Trialco violated two sets of rules: The National Emission Standards for Hazardous Pollutants (NESHAP) for secondary aluminum production facilities, found in 40 CFR part 63, subpart RRR. The facility’s Federally Enforceable State Operating Permit (FESOP) for its Chicago Heights location. According to the proposed Consent Decree, Trialco Aluminum, LLC will do several things: Pay a civil penalty of $1 million. Do an updated assessment of its capture and collection system for emissions. Adopt and use a new Operation, Maintenance, and Monitoring (OM&M) plan. Apply for a new FESOP, which must include revised operating limits. The DOJ has opened a public comment period for this Consent Decree. Comments should be sent to the Assistant Attorney General, Environment and Natural Resources Division. All comments must refer to United States v. Trialco Aluminum, LLC, D.J. Ref. No. 90-5-2-1-12888. The deadline to submit comments is 30 days after this notice was published. Comments can be sent by email or mail: By email: [email protected] By mail: Assistant Attorney General, U.S. DOJ–ENRD, P.O. Box 7611, Washington, DC 20044-7611. Any comment sent in writing, or at a public meeting, may be filed in the public court docket without giving notice to the commenter. During the public comment period, the full Consent Decree can be read and downloaded from the DOJ’s website at http://www.justice.gov/enrd/consent-decrees. If help is needed to access the Consent Decree, assistance can be requested using the same email or mail address as for comments. This notice was signed by Laura Thoms, Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. For further details, see Federal Register Volume 90, Number 129, published on July 9, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Ohio Doctor Loretta Clement’s Registration to Handle Controlled Substances Estimated reading time: 3–5 minutes The Drug Enforcement Administration (DEA) has revoked the Certificate of Registration No. FC2337500 for Loretta Clement, M.D., of Cincinnati, Ohio. Dr. Clement is now barred from prescribing, administering, dispensing, or otherwise handling controlled substances in Ohio. The DEA issued an Order to Show Cause (OSC) to Dr. Clement on February 18, 2025. The order said her registration should be revoked because she does not have the legal authority to prescribe controlled substances in Ohio. She did not request a hearing about this order. The DEA confirmed the OSC was sent to Dr. Clement by email after attempts to serve her at her home and offices failed. The DEA Diversion Investigator spoke with Dr. Clement by phone and explained the process. The State Medical Board of Ohio suspended Dr. Clement’s license on or about August 14, 2024. The agency checked the official Ohio state records and confirmed that Dr. Clement’s medical license is inactive. Dr. Clement may dispute this fact by filing a motion within fifteen days of the order. DEA rules say that a doctor must have state authority to prescribe controlled substances in order to have a DEA registration. When a doctor loses that authority, the DEA is allowed to revoke the registration. Under Ohio law, only doctors with a valid license may prescribe or handle these medicines. Because Dr. Clement’s medical license is not active, she is not allowed to prescribe or handle controlled substances in Ohio. The DEA therefore ordered her registration revoked. The decision was signed on July 1, 2025, by Acting Administrator Robert J. Murphy. The order takes effect August 6, 2025. Any new or pending applications by Dr. Clement to renew, modify, or add DEA registration in Ohio are denied. This notice was published in the Federal Register, Volume 90, Number 127, pages 29885-29886, on July 7, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Medical License of Loretta Clement, M.D. Estimated reading time: 2–4 minutes Background On February 18, 2025, the DEA sent an Order to Show Cause to Dr. Clement. This order explained that her registration would be revoked. The reason was that Dr. Clement could no longer prescribe, handle, or dispense controlled substances in Ohio. This is because she does not have a valid medical license in the state. Dr. Clement did not ask for a hearing about this decision. The DEA mailed and emailed the order to her. She did not reply. The DEA investigator also called Dr. Clement and explained the process. Because she did not respond, the DEA counted her as “in default.” In such cases, the Agency admits the government’s facts as true. Findings In August 2024, the State Medical Board of Ohio suspended Dr. Clement’s license to practice medicine. The DEA checked the State of Ohio’s license database. Her license is listed as inactive. This means, as of July 2025, Dr. Clement cannot work as a doctor in Ohio. Legal Basis Federal law says a doctor must have a valid state license to handle controlled drugs. Once Dr. Clement’s state license was suspended, she could not legally prescribe or handle those substances. The DEA must revoke registration when a doctor does not have this state authority. Ohio law also requires any person prescribing drugs to be authorized under state law. Only doctors with valid licenses are allowed to prescribe or administer controlled substances. Dr. Clement’s suspension means she is no longer authorized to do this. Order and Next Steps DEA Acting Administrator Robert J. Murphy signed the order on July 1, 2025. The order revokes Dr. Clement’s DEA Certificate of Registration, number FC2337500. It also denies any current or future applications by Dr. Clement to renew or modify her registration, or to gain new registrations in Ohio. The order will take effect on August 6, 2025. Official Filing The notice was filed with the Federal Register by Heather Achbach, Federal Register Liaison Officer for the DEA. The DEA’s actions follow all guidelines in the law and DEA regulations. End of Notice Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Announces Intent to Temporarily Schedule Seven Benzimidazole-Opioids as Schedule I Substances Estimated reading time: 5–6 minutes Background The Drug Enforcement Administration (DEA) plans to temporarily place seven benzimidazole-opioids into Schedule I of the Controlled Substances Act (CSA). This move follows concerns that these synthetic opioids pose an imminent danger to public safety. Ethyleneoxynitazene Methylenedioxynitazene (also called 3′,4′-methylenedioxynitazene) 5-methyl etodesnitazene N-desethyl etonitazene N-desethyl protonitazene N,N-dimethylamino etonitazene N-pyrrolidino isotonitazene When the temporary scheduling order is published after July 28, 2025, these substances will be subject to all regulations, civil, and criminal penalties applicable to Schedule I controlled substances. Legal Framework Under 21 U.S.C. 811(h), the DEA may schedule substances temporarily for two years if it is necessary to avoid an imminent hazard to public safety. This can be extended for up to one year if certain proceedings are initiated. A substance can only be temporarily scheduled in Schedule I if it is not already scheduled elsewhere, and if there is no FDA approval for its medical use. According to the DEA and Health and Human Services (HHS), none of these seven substances are approved for medical use in the United States. History and Pattern of Abuse Benzimidazole-opioids were first created in the 1950s for pain relief but were never approved for medical use. Since 2019, these opioids—also called “nitazenes”—started showing up in illegal drug markets in the U.S. They are usually found as powders or tablets, often mixed with other drugs. These substances have been linked to a growing number of overdose deaths. Reports have found them in both drug seizures and in biological samples from fatal cases. Current Abuse and Law Enforcement Encounters Since 2023, there have been 184 reports related to these seven substances in the National Forensic Laboratory Information System (NFLIS-Drug) database. Here are the reported state encounters: Ethyleneoxynitazene: 14 encounters in 5 states Methylenedioxynitazene: 19 encounters in 5 states 5-methyl etodesnitazene: 4 encounters in 1 state N-desethyl etonitazene: 114 encounters in 14 states N-desethyl protonitazene: 9 encounters in 6 states N,N-dimethylamino etonitazene: 12 encounters in 4 states N-pyrrolidino isotonitazene: 12 encounters in 9 states These drugs are often abused along with other powerful substances such as fentanyl, heroin, or designer benzodiazepines. Public Health Risks These benzimidazole-opioids act like other strong opioids, affecting mu-opioid receptors in the brain. They can cause serious health effects, including respiratory depression and death. In 2024, these substances were found in at least 37 toxicology cases. They have no accepted medical use. People who use drugs from unknown sources may be at higher risk since the exact content and strength are uncertain. The spread of these substances makes the ongoing opioid crisis even worse. Regulatory Process and Next Steps The DEA followed all legal steps: Gave notice to the HHS, who did not object. Is giving the public 30 days’ notice before the order is published. Once the temporary order is in effect, these seven substances will: Be illegal to make, distribute, or possess except as allowed by law. Be regulated with the same controls as other Schedule I substances. This action will last for two years, with the possibility of a one-year extension as DEA works on permanent scheduling rules. Federal Rulemaking Temporary scheduling is issued as an “order” and not a “rule.” Regular rulemaking, which takes longer and allows more public input, will continue to determine if these drugs should be permanently scheduled. Summary Table of Scheduled Substances Substance DEA Code Ethyleneoxynitazene 9770 Methylenedioxynitazene 9766 5-methyl etodesnitazene 9767 N-desethyl etonitazene 9768 N-desethyl protonitazene 9769 N,N-dimethylamino etonitazene 9771 N-pyrrolidino isotonitazene 9772 Authority This action was signed on June 17, 2025, by Acting DEA Administrator Robert J. Murphy. For more details, the public can review the full notice and supporting material under Docket Number DEA-1494 at www.regulations.gov. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Bohdan Olesnicky, M.D.’s Certificate to Handle Controlled Substances in California Estimated reading time: 2–3 minutes On June 26, 2025, the Drug Enforcement Administration (DEA) published a decision and order to revoke the Certificate of Registration No. FO0628391 for Bohdan Olesnicky, M.D., of Indian Wells, California. The DEA took action because Dr. Olesnicky does not have authority to handle controlled substances in California. On December 5, 2023, Dr. Olesnicky surrendered his California physician’s and surgeon’s license. The DEA explained that holding a valid state license is required to handle controlled substances. The DEA cited the Controlled Substances Act, which says a practitioner must be authorized by the state to dispense controlled substances. The DEA stated that California law requires a “practitioner” to be licensed to distribute, dispense, or handle controlled substances. Since Dr. Olesnicky is no longer licensed in California, he is not allowed to handle these substances in the state. The DEA made efforts to notify Dr. Olesnicky about the action. On November 15, 2024, the DEA left a copy of the Order to Show Cause (OSC) at Dr. Olesnicky’s address. They also tried to contact him by email and certified mail. The DEA found these steps met the legal requirements for giving notice. Dr. Olesnicky did not respond to these notices or request a hearing. According to DEA rules, this is treated as a waiver of his right to a hearing and as an admission of the facts in the order. Because Dr. Olesnicky is no longer allowed to practice medicine in California, the DEA ordered the following: The Certificate of Registration No. FO0628391 for Dr. Olesnicky is revoked. Any applications to renew or change this registration are denied. Any other application for a DEA registration in California by Dr. Olesnicky is denied. This order becomes effective July 28, 2025. The decision was signed by Acting Administrator Robert J. Murphy on June 20, 2025, and published in the Federal Register. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Seattle Nurse Practitioner’s Registration for Violating Controlled Substances Laws Estimated reading time: 4–6 minutes On June 26, 2025, the Drug Enforcement Administration (DEA) published an official notice revoking the DEA Certificate of Registration for Scott Hansen, A.P.R.N., a nurse practitioner based in Seattle, Washington. This action follows a series of violations concerning controlled substances and failure to maintain proper state licensing. Immediate Suspension and Order to Show Cause On July 18, 2024, the DEA issued an Order to Show Cause and Immediate Suspension of Registration (OSC/ISO) to Scott Hansen. The order stated that Hansen’s DEA registration, No. MH7100124, was suspended under federal law because his continued registration posed “an imminent danger to the public health or safety.” The DEA also proposed revocation of Hansen’s registration, stating that his conduct was inconsistent with the public interest and that he no longer had state authority to handle controlled substances in Washington State, where he was registered. Prescriptions Written After License Suspension According to the DEA, Hansen prescribed at least five controlled substances after his Washington advanced registered nurse practitioner (ARNP) license was indefinitely suspended by the Washington State Board of Nursing on March 5, 2024. Hansen issued prescriptions for medications including amphetamine/dextroamphetamine, lisdexamfetamine, oxycodone/acetaminophen, and buprenorphine between March 19 and April 19, 2024, during which he did not have a valid ARNP license. Violation of State and Federal Law Federal law requires registrants to be authorized to dispense controlled substances under the laws of the state in which they practice. Washington law mandates that only a licensed ARNP may prescribe or deliver controlled substances, and unlicensed practice is unlawful. The DEA found Hansen lacked state authority to practice and therefore was not eligible to maintain his DEA registration. Writing prescriptions while unlicensed violated the Controlled Substances Act and Washington state law. Notification and Service The DEA made multiple attempts to serve the OSC/ISO to Hansen, including visiting his registered and mailing addresses, contacting the realtor involved in the sale of Hansen’s house, and attempting to reach him by phone, voicemail, text, and email. The DEA determined that Hansen was successfully served by email. Hansen did not request a hearing nor respond to the allegations. Grounds for Revocation According to the DEA, there are two main grounds for revocation: Hansen lost his state authority to handle controlled substances when his ARNP license was suspended. Hansen’s continued registration was inconsistent with the public interest because of repeated violations, including prescribing without state authorization. The DEA found that these actions were outside the usual course of professional practice and were not for a legitimate medical purpose. Public Interest Consideration The Controlled Substances Act requires DEA registrants to comply with strict rules to help control drug abuse and trafficking. Hansen’s actions, issuing prescriptions without proper state licensing, went against these principles. The DEA weighed all required public interest factors and determined that Hansen’s violations, along with his failure to respond or take responsibility, provided a strong basis for revocation. Order Effective July 28, 2025 The DEA revoked Scott Hansen’s DEA Certificate of Registration, No. MH7100124, effective July 28, 2025. The DEA also denied any of Hansen’s pending applications for renewal, modification, or additional registrations for controlled substances in Washington. The order was signed by Acting Administrator Robert J. Murphy on June 20, 2025, and officially published in the Federal Register. Contact Information Any challenges to the DEA’s findings can be filed within fifteen calendar days of the order. Reference Federal Register Volume 90, Number 121 (Thursday, June 26, 2025), Pages 27338-27341, Document Number 2025-11731. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

National Institute of Corrections Advisory Board Schedules Public Meeting for July 15, 2025 Estimated reading time: 1–7 minutes The National Institute of Corrections (NIC) Advisory Board will hold a meeting on Tuesday, July 15, 2025. This meeting will take place virtually. The public session is from 1:00 p.m. to 4:00 p.m. Eastern Time. A closed session will follow from 4:00 p.m. to 4:30 p.m. Eastern Time. The NIC Advisory Board helps NIC make long-range plans. The board gives advice on program development. They guide NIC on training, technical help, information services, and policy development. These services support corrections agencies at the federal, state, and local levels. Leslie LeMaster is the Designated Federal Officer for the meeting. NIC is located at 320 First Street NW, Room 901-3, Washington, DC 20534. You can call Ms. LeMaster at (202) 305-5773 or email her for more information. On July 15, the board will hear a report from the NIC Director. Each division of NIC will also give updates about their projects. There will be time for board members to ask questions and share guidance. The public can join the meeting virtually. People can offer their ideas and comments in person or in writing. Requests to join and present must be submitted to Ms. LeMaster by Monday, July 7, 2025. There is a public comment period from 3:35 p.m. to 3:50 p.m. Each person or group will have a limited amount of time to speak. People who want to present should give the topic, names, titles, agencies, addresses, emails, and the time needed by July 7, 2025. The session from 4:00 p.m. to 4:30 p.m. will be closed. This part is private so that the board can discuss internal personnel rules and practices or personal information, as allowed by law. NIC will try to help everyone attend the meeting. If you need special help due to a disability, contact Leslie LeMaster by July 7, 2025. This notice follows the Federal Advisory Committee Act (5 U.S.C. app. 2). Leslie LeMaster is listed as the contact person and the Designated Federal Officer for the National Institute of Corrections. The official notice was filed on June 25, 2025. The meeting is announced in accordance with legal requirements. The billing code for this notice is 4410-36-P. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Rust Foundation Updates Membership in National Research Venture Estimated reading time: 2–4 minutes On May 27, 2025, the Rust Foundation made official notifications with the Attorney General and the Federal Trade Commission. These notifications were made under section 6(a) of the National Cooperative Research and Production Act of 1993. The law is found in 15 U.S.C. 4301 et seq. The notifications shared new changes in group membership. Five new parties have joined the Rust Foundation’s research project. They are: Fledgio Limited, London, UNITED KINGDOM OpenAtom Foundation, Beijing, PEOPLE’S REPUBLIC OF CHINA School of Computer Science at University of Bristol, Bristol, UNITED KINGDOM Stichting Trifecta Tech Foundation, Nijmegen, KINGDOM OF THE NETHERLANDS Tock Foundation, Seattle, WA Three organizations have withdrawn as parties in the project. They are: Dropbox Inc., San Francisco, CA Embecosm, Southampton, UNITED KINGDOM Knoldus Inc., Missisauga, CANADA No other changes have taken place in either the membership or planned work of the research group. The membership in the group research project continues to stay open. The Rust Foundation will send more written notifications when new members join or leave. The Rust Foundation first filed a notification for this venture on April 14, 2022. The Department of Justice published notice of that filing in the Federal Register on May 13, 2022 (87 FR 29384). The most recent notification before this was filed on March 19, 2025. Notice of that was published in the Federal Register on April 21, 2025 (90 FR 16702). This information was filed by Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division, at the Department of Justice. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Notice of ASTM International Filing Published in the Federal Register Estimated reading time: 1–3 minutes On June 20, 2025, the Department of Justice announced an official notice from ASTM International. This notice appears in Volume 90, Number 117 of the Federal Register, on page 26328. The notice states that ASTM International has filed written notifications as of May 22, 2025. The filing is under section 6(a) of the National Cooperative Research and Production Act of 1993, found at 15 U.S.C. 4301 et seq., also known as “the Act.” ASTM International sent these notifications to both the Attorney General and the Federal Trade Commission. The purpose of the notification is to extend the protections in the Act. These protections limit what antitrust plaintiffs can recover to only actual damages under specific situations. The content of the filing from ASTM International contains an updated list of ongoing standards development activities. These activities are called “Work Items,” and they started between February 17, 2025, and May 13, 2025. Each Work Item has a brief description and is listed on the ASTM website at http://www.astm.org. ASTM International first filed a notification for these purposes on September 15, 2004. The Department of Justice then published a notice about it in the Federal Register on November 10, 2004, found at 69 FR 65226. The most recent prior notification from ASTM was filed on February 28, 2025. That notice appeared in the Federal Register on April 21, 2025, at 90 FR 16701. Suzanne Morris, Deputy Director of Civil Enforcement Operations at the Antitrust Division, certified this notice. The document’s reference number is 2025-11311. It was filed on June 18, 2025, at 8:45 am. The Department of Justice Antitrust Division’s billing code for this notice is 4410-11-P. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

AJNA Biosciences Applies to Make Psilocybin and Psilocyn in Colorado Estimated reading time: 2–3 minutes What AJNA Wants to Do AJNA Biosciences wants to make mushrooms that contain Psilocybin and Psilocyn. These are both schedule I controlled substances. The company’s work is for internal research, clinical trials, and analysis. AJNA also wants to sell these substances to its customers who do schedule I clinical research. Where and When AJNA Biosciences is located at 8022 Southpark Circle, Suite 500, Littleton, Colorado 80120-5659. The company sent its application on May 7, 2025. Rules and Details The DEA says this notice is made under 21 CFR 1301.33(a). Anyone who is a registered bulk manufacturer or an applicant for the same substances can comment or object. They have until August 18, 2025, to do this. They may also ask for a hearing by the same date. How to Comment Comments need to be sent electronically through the Federal eRulemaking Portal at https://www.regulations.gov. People can write short comments or attach longer files. After sending a comment, a Comment Tracking Number is given. Comments may not show up right away on the site. Who Signed the Notice Matthew Strait, Deputy Assistant Administrator at the DEA, signed the notice. No activities except for those listed are allowed for this registration. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Posts Notice on NFPA Standards Activity Estimated reading time: 3–5 minutes The Department of Justice has published an official notice in the Federal Register on June 13, 2025. This notice is about the National Fire Protection Association (NFPA) and its work on developing safety standards. On May 1, 2025, the NFPA filed written notifications under section 6(a) of the National Cooperative Research and Production Act of 1993. The NFPA sent this notice to the Attorney General and the Federal Trade Commission. This is part of their regular process when updating their standards development activities. The NFPA’s filing is meant to extend the protection of the Act. This Act limits the recovery of antitrust damages to actual damages in certain situations. The NFPA has sent an updated list about its standards development. This includes information on their technical committees and assessment work. The NFPA releases information about its regulations, current standards, standards development, and assessment activities to the public. This information is available on the NFPA website at nfpa.org. The NFPA first notified the Department of Justice under this Act on September 20, 2004. The first notice was published in the Federal Register on October 21, 2004. The most recent notification before this one was filed on January 24, 2025. That notice was published on February 28, 2025. Suzanne Morris, Deputy Director of Civil Enforcement Operations at the Antitrust Division, signed this latest notice. The notice was printed under [FR Doc. 2025-10768]. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

New Venture on Electrified Vehicle and Energy Storage Announced Estimated reading time: 3–5 minutes On April 3, 2025, a notice was filed with the Department of Justice Antitrust Division. It is about Electrified Vehicle and Energy Storage Evaluation–II (EVESE II). This notice is under the National Cooperative Research and Production Act of 1993. The purpose is to let the public know which companies are working together, and what the group intends to do. The notice lists the parties in the EVESE II venture. These are: BAE Systems Controls Inc., from Endicott, New York Castrol Limited, from Reading, United Kingdom Ford Motor Company, from Dearborn, Michigan Honda Development & Manufacturing of America, LLC, from Marysville, Ohio Komatsu America Corp, from Chicago, Illinois The companies plan to better understand battery energy storage systems. This work is for vehicles and other uses. They will study batteries in both normal use (called cycling) and in unusual or extreme use (called abuse). The research will focus on three main areas. These are: the battery cell, the battery module, and applications of the battery. The notice says this information is being made public to limit damages if there are any antitrust lawsuits. The Deputy Director for Civil Enforcement Operations in the Antitrust Division, Suzanne Morris, signed the notice. This entry is documented in the Federal Register, Volume 90, Number 113, Page 25081. The filing date was June 12, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.